Ron Piervincenzi Named Next CEO of USP - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ron Piervincenzi Named Next CEO of USP


The Board of Trustees of the United States Pharmacopeial Convention (USP) today announced that Ron Piervincenzi will become the chief executive officer of USP and chair of USP’s standards-setting body, the Council of Experts. Piervincenzi will assume these responsibilities Feb. 1, 2014.

“I am excited and honored to lead USP’s mission to improve global health,” said Piervincenzi. “This is an outstanding organization doing life-changing work around the world, and I look forward to focusing the collective energy, expertise and knowledge of USP’s global volunteers and staff on the challenges of the future.”

“In Dr. Piervincenzi we have found an outstanding new leader for USP, which has seen unprecedented growth over the past several years,” said USP Board of Trustees Chair, Thomas R. Temple, R.Ph., M.S. “I am excited about Dr. Piervincenzi’s commitment to the next phase of USP’s unique mission to develop and promote cutting edge global standards for pharmaceuticals, food, and dietary supplements.”

Piervincenzi was a partner and leader in McKinsey & Company's Global Pharmaceutical and Medical Products Practice for 12 years where, among other responsibilities, he launched McKinsey's global drug safety, medical and regulatory service line.  Dr. Piervincenzi earned an MS and PhD from Duke University in Biomedical Engineering with research focused on protein engineering.

Source: US Pharmacopeial Convention (USP)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here